Clinical Trials Logo

SARS Pneumonia clinical trials

View clinical trials related to SARS Pneumonia.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04393051 Not yet recruiting - Covid-19 Clinical Trials

Baricitinib Compared to Standard Therapy in Patients With COVID-19

BARICIVID-19
Start date: May 20, 2020
Phase: Phase 2
Study type: Interventional

There is urgent need of an effective therapy for Covid-19. To date, the best treatment of SARS-CoV-2 infection is unknown. Baricitinib has been identified as potential treatment for 2019-nCoV acute respiratory disease, because of its immunomodulating and hypothesized antiviral activity. This is a multicenter randomized clinical trial that aims to evaluate the efficacy and safety of baricitinib in patients with SARS-CoV2 pneumonia. Patients will be randomized to receive or not baricitinib as adjunctive therapy. All patients will continue to receive the ongoing standard therapy: chloroquine/idrossichloroquine and low-molecular weight heparin (LMWH) eventually associated with ritonavir/lopinavir or darunavir/ritonavir will be allowed for all included patients. The primary endpoint measure is the efficacy of baricitinib in reducing the number of patients requiring invasive ventilation after 7 and 14 days of treatment. Secondary endpoints will be mortality rates and toxicity of baricitinib.